Why Is Foghorn Therapeutics ( $FHTX) Stock Down -29.82% Today? (Find out why any stock moved today on Tickeron.) Shares plunged roughly 29.8% to about $2.05, down from the prior session's close of $2.92. Primary catalyst: Foghorn and Eli Lilly terminated their oncology collaboration and discontinued FHD-909 after Phase 1 data showed insufficient clinical efficacy. Secondary drivers: A wave of analyst downgrades and price-target cuts, plus a roughly 40% workforce reduction. Broader context: The decline compounds an 18% slump the previous session, pushing shares near record lows and deepening a year-to-date sell-off of roughly 60%. $MGTX $ARVN $EDIT $PRTA